J. Herndon

发表

The Association of Intratumoral Germinal Centers with Early-Stage Non-small Cell Lung Cancer

R. Bentley, E. Gottlin, M. Campa, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

J. Herndon, Mark R. Green, R. Dillman, 1996, Journal of the National Cancer Institute.

IDH1 and IDH2 mutations in gliomas.

R. McLendon, A. Friedman, B. Vogelstein, 2009, The New England journal of medicine.

Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax.

J. Herndon, E. Patz, J. Erasmus, 1999, Radiology.

Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation.

H Page McAdams, Edith M Marom, J. Herndon, 2004, Radiology.

Panel of serum biomarkers for the diagnosis of lung cancer.

Irina Kusmartseva, Michael J Campa, Edward F Patz, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group Trial

Sheryl G. A. Gabram, Kelly K. Hunt, A. Marilyn Leitch, 2006, Annals of Surgical Oncology.

A design alternative for two-stage, phase II, multicenter cancer clinical trials.

J. Herndon, J E Herndon, James E. Herndon, 1998, Controlled clinical trials.

High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer

D. Harpole, J. Herndon, K. Danenberg, 2005, Clinical Cancer Research.

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.

J. Herndon, M. Green, G. Clamon, 1996, Lung cancer.

Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non‐small cell lung cancer

J. Herndon, J. Crawford, K. Leopold, 1994, Cancer.

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

Darell D. Bigner, Allan H. Friedman, Jeremy N. Rich, 2007, Clinical Cancer Research.

Weekly, high‐dose paclitaxel in advanced lung carcinoma

M. Ratain, J. Herndon, D. Hollis, 2003, Cancer.

Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations.

Edward F Patz, S. Swensen, J. Herndon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In reply [4]

S. Swensen, J. Herndon, E. Patz, 2005 .

A Phase II Study of Recombinant Interferon‐Gamma Following Combination Chemotherapy for Patients with Extensive Small Cell Lung Cancer

J. Herndon, D. Hollis, Mark R. Green, 1995, American journal of clinical oncology.

High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.

R. McLendon, A. Friedman, J. Provenzale, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.

J. Herndon, J. Erasmus, H. McAdams, 2002, AJR. American journal of roentgenology.

Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B.

J. Holland, J. Herndon, T. Ahles, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapy

J. Holland, E. Winer, J. Herndon, 2005, Cancer.

Cytologically proved malignant pleural effusions: distribution of transudates and exudates.

J. Herndon, E. Patz, J. Caruso, 1998, Chest.

An Analysis of Radiotherapy Data from the CNS Cancer Consortium's Randomized Prospective Trial Comparing AZQ to BCNU in the Treatment of Patients with Primary Malignant Brain Tumors

L. Gaspar, J. Herndon, E. Halperin, 1993, American journal of clinical oncology.

A phase III randomized prospective trial of external beam radiotherapy (ERT), mitomycin C (MITO), BCNU, and 6-mercaptopurine (6-MP) for the treatment of adults with anaplastic glioma of the brain

A. Friedman, S. Rosenfeld, L. Gaspar, 1994 .

Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.

R. Clough, M. Anscher, J. Herndon, 2003, International journal of radiation oncology, biology, physics.

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

J. Herndon, E. Vokes, Mark R. Green, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636.

J. Herndon, S. Seagren, M. Green, 1994, International journal of radiation oncology, biology, physics.

A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B.

J. Herndon, J. Rosenman, W. Eaton, 1994, Cancer investigation.

Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer.

A. Giuliano, L. Newman, K. Hunt, 2005, American journal of surgery.

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

R. McLendon, A. Friedman, R. Verhaak, 2021, Nature communications.

Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial.

G. Patterson, D. Harpole, J. Herndon, 2005, Lung cancer.

High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.

J. Herndon, N. Vogelzang, M. Green, 2001, Lung cancer.

Predicting the sites of metastases from lung cancer using molecular biologic markers.

D. Harpole, J. Herndon, M. Kinch, 2001, The Annals of thoracic surgery.

Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors.

J. Herndon, B. Brigidi, L. Forman, 2008, Neuro-oncology.

Adverse Events in Total Knee Arthroplasty: A National Medicare Study

W. Maloney, J. Herndon, J. Huddleston, 2009 .

FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non–Small-Cell Lung Cancer

J. Herndon, E. Patz, B. Howard, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study.

D. Sugarbaker, J. Herndon, S. Swanson, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

phase II, multi-institutional cooperative group study in high-risk patients: The Cancer and Leukemia Group B (CALGB) 9335, a Video-assisted wedge resection and local radiotherapy for peripheral lung cancer

J. Herndon, J. Bogart, R. Keenan, 2013 .

Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study.

D. Sugarbaker, J. Herndon, Mark R. Green, 2005, The Journal of thoracic and cardiovascular surgery.

Preoperative Exercise Vo2 Measurement for Lung Resection Candidates: Results of Cancer and Leukemia Group B Protocol 9238

Kemp Kernstine, Dorothy Watson, D. Sugarbaker, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage.

J. Herndon, E. Patz, R. Gilkeson, 1998, Chest.

Angiographic follow-up after internal mammary artery graft angioplasty.

R. Califf, J. Herndon, D. Glower, 1992, The American journal of cardiology.

Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities.

D. Harpole, J. Herndon, E. Patz, 2001, Cancer detection and prevention.

Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.

G. Bepler, M. Campa, J. Herndon, 2004, Lung cancer.

Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer.

J. Herndon, E. Patz, H. McAdams, 1999, AJR. American journal of roentgenology.

Quality of life impact of three different doses of suramin in patients with metastatic hormone‐refractory prostate carcinoma

J. Holland, M. Ratain, David Palchak, 2004, Cancer.

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.

N. Choi, J. Herndon, J. Rosenman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083.

J. Herndon, Mark R. Green, W. Eaton, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply to A. Katz et al

R. Schilsky, J. Herndon, G. Strauss, 2009 .

Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.

R. Coleman, J. Herndon, E. Patz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group.

D. Sugarbaker, J. Herndon, Mark R. Green, 1995, The Journal of thoracic and cardiovascular surgery.

Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study.

N. Choi, D. Mathisen, J. Herndon, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-183 A phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC): CALGB 9734

M. Socinski, R. Govindan, J. Herndon, 2003 .

Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): Initial analysis of a randomized phase III trial.

J. Herndon, E. Vokes, M. Kelley, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.

J. Herndon, E. Patz, S. Cheran, 2004, Lung cancer.

Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.

J. Herndon, E. Vokes, Mark R. Green, 2008, Lung cancer.

236 Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (INDCT) followed by concomitant chemoradiotherapy (XRT) in stage IIIB non small cell lung cancer (NSCLC): Toxicity data (CALGB study 9431)

Michael R. Green, J. Herndon, E. Vokes, 1997 .

Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non‐small cell lung cancer in CALGB protocol #8935

W. Richards, D. Sugarbaker, J. Herndon, 2006, Journal of surgical oncology.

Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.

R. Govindan, J. Herndon, N. Rizvi, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

In reply [12]

S. Swensen, J. Herndon, E. Patz, 2005 .

Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme

R. McLendon, A. Friedman, D. Bigner, 2009, Clinical Cancer Research.

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

J. Herndon, E. Vokes, M. Kelley, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness

C. Desch, J. Herndon, Mark R. Green, 2001 .

Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial.

V. Rusch, B. Meyers, John D. Mitchell, 2006, The Annals of thoracic surgery.

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2

R. Govindan, J. Herndon, Mark R. Green, 2005, Cancer.

Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).

J. Herndon, Mark R. Green, Antonius A. Miller, 2005, Lung cancer.

Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection.

M. Joshi, D. Harpole, J. Herndon, 2003, The Annals of thoracic surgery.

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

W. Richards, D. Sugarbaker, D. Harpole, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.

R. Salgia, D. Harpole, J. Herndon, 2000, Anticancer research.

Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.

J. Herndon, M. Green, S. Fleishman, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.

D. Harpole, J. Herndon, J. Marks, 1995, Cancer research.

Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening.

J. Herndon, E. Patz, P. Goodman, 2001, Cancer.

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non‐small cell lung cancer a cancer and leukemia group B study

J. Herndon, Mark R. Green, M. Green, 1993, Cancer.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

M. Socinski, S. Zhou, M. Anscher, 2001, The oncologist.

Thorascopic wedge resection and radiotherapy for T1N0 non-small cell lung cancer (NSCLC) in high risk patients: Preliminary analysis of a cancer and leukemia group B and Eastern Cooperative Oncology Group phase II trial

Michael R. Green, D. Sugarbaker, J. Herndon, 2000 .

A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931.

J. Herndon, Mark R. Green, M. Green, 1997, Controlled clinical trials.

[18F]Fluorodeoxyglucose-Positron Emission Tomography in Patients with Medulloblastoma

R. Coleman, J. Herndon, T. George, 2004, Neurosurgery.

Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.

J. Herndon, D. Hollis, W. Eaton, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme

G. Riggins, D. Bigner, J. Herndon, 2006, Clinical Cancer Research.

Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma.

V. Lowe, J. Herndon, E. Patz, 1995, Chest.

T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.

J. Herndon, E. Patz, E. Marom, 2002, Radiology.

Staging non-small cell lung cancer with whole-body PET.

P C Goodman, R. Coleman, J. Herndon, 1999, Radiology.

Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis.

J. Herndon, E. Patz, J. Erasmus, 1999, Radiology.

Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.

E. Scalzetti, W. Richards, D. Sugarbaker, 2005, Chest.

Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.

Jeffrey E. Lee, M. Ross, D. Fraker, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of carboplatin, etoposide and exisulind in patients with extensive stage small cell lung cancer: CALGB 30104

Michael R. Green, R. Govindan, J. Herndon, 2005 .

Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.

J. Herndon, E. Vokes, M. Kelley, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430

T. Lynch, J. Herndon, E. Vokes, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing.

J. Herndon, L. Wasserman, T. Prior, 2003, The Journal of molecular diagnostics : JMD.

Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.

J. Herndon, Mark R. Green, H. Kindler, 2005, Lung cancer.

Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial.

E. Winer, D. Smith, J. Herndon, 1992, Cancer research.

73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.

P. Maguire, R. Clough, M. Anscher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

73.6 G y a nd B eyond: H yperfractionate d, A ccelerated Radiotherapy f or N on-Small-Cell L ung C ancer

P. Maguire, R. Clough, M. Anscher, 2001 .

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

J. Herndon, N. Vogelzang, M. Green, 2001, Lung cancer.

796 Prevention of chemotherapy related anemia by recombinant human erythropoietin (EPO) in patients with small cell lung cancer (SCLC) receiving cyclophosphamide, doxorubicin, and etoposide (CAE) chemotherapy with G-SCF support

E. Winer, J. Herndon, J. Crawford, 1997 .

Pleural effusions in lung transplant recipients: image-guided small-bore catheter drainage.

J. Herndon, J. Erasmus, H. McAdams, 2003, Radiology.

Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).

J. Herndon, D. Hollis, S. Luikart, 1997, American journal of clinical oncology.

Glycoprotein Nonmetastatic Melanoma Protein B, a Potential Molecular Therapeutic Target in Patients with Glioblastoma Multiforme

G. Riggins, D. Bigner, J. Herndon, 2006, Clinical Cancer Research.

Local Excision of Distal Rectal Cancer: An Update of Cancer and Leukemia Group B 8984

J. Herndon, J. Greenberg, D. Shibata, 2008, Diseases of the colon and rectum.

Phase II Trial of Vinorelbine Plus Doxorubicin in Relapsed Small-Cell Lung Cancer: CALGB 9332

D. Lake, T. Lynch, J. Herndon, 2004, American journal of clinical oncology.

70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808.

J. Herndon, A. Turrisi, Mark R. Green, 2004, International journal of radiation oncology, biology, physics.

A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study.

J. Herndon, S. Luikart, C. Cirrincione, 1996, Lung cancer.

Running Head: EXERCISE AND BREAST CANCER Effect of Aerobic Exercise on Tumor Physiology in an Animal Model of Human Breast Cancer

M. Dewhirst, S. Keir, J. Herndon, 2009 .

Tumor marker expression is predictive of survival in patients with esophageal cancer.

C. Reed, D. Harpole, J. Herndon, 2001, The Annals of thoracic surgery.

Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial

Michael R. Green, J. Herndon, E. Vokes, 2004 .

CALGB 140803-Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: Ancillary analysis of protocol 9238.

J. Herndon, L. Jones, N. Eves, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy

J. Herndon, J. Sampson, Anirudh Saraswathula, 2016, Cancer Immunology, Immunotherapy.

Modulation of 06-Alkylguanine-DNA Alkyltransferase-mediated Carmustine Resistance Using Streptozotocin: A Phase I Trial1

David C. Smith, E. Winer, J. Herndon, 2006 .

Dihydro‐5‐azacytidine in malignant mesothelioma

M. Citron, J. Herndon, Mark R. Green, 1997, Cancer.

Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).

T. Lynch, J. Herndon, A. Turrisi, 2002, Clinical lung cancer.

Survival analysis of presumptive prognostic markers among oligodendrogliomas

R. McLendon, A. Friedman, B. A. Rasheed, 2005, Cancer.

MTAP loss promotes stemness in glioblastoma and confers unique susceptibility to purine starvation.

R. McLendon, A. Friedman, S. Murphy, 2019, Cancer research.

MRP3: a molecular target for human glioblastoma multiforme immunotherapy.

R. McLendon, G. Riggins, D. Bigner, 2010, BMC Cancer.

Haptoglobin and posttranslational glycan‐modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer

E. Gottlin, M. Campa, J. Herndon, 2007, Cancer.

Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

R. McLendon, D. Bigner, J. Herndon, 2004, The Journal of molecular diagnostics : JMD.

Alterations of the TP53 gene in human gliomas.

R. McLendon, A. Friedman, D. Bigner, 1994, Cancer research.

Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.

R. Clough, M. Anscher, J. Herndon, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

David J Sugarbaker, Richard L Schilsky, R. Schilsky, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope

J. Herndon, S. Nair, J. Sampson, 2021, NPJ vaccines.

Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients

R. McLendon, A. Friedman, D. Bigner, 2015, Nature.

Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.

J. Herndon, D. Hollis, M. Green, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer.

J. Herndon, Mark R. Green, D. Watson, 2004, Lung cancer.

Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma

D. Sugarbaker, J. Herndon, D. Kwiatkowski, 1999, Cancer.

Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.

W. Richards, D. Sugarbaker, D. Harpole, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

J. Herndon, Mark R. Green, N. Vogelzang, 1998, Chest.

Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633.

R. Schilsky, D. Sugarbaker, J. Herndon, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.

J. Herndon, E. Vokes, J. Atkins, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers.

D. Harpole, J. Herndon, T. D’amico, 1999, The Journal of thoracic and cardiovascular surgery.

Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B

R. Govindan, J. Herndon, R. Kratzke, 2005, Clinical Cancer Research.

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

W. Barry, J. Herndon, M. Kelley, 2017, Cancer investigation.

O-277 CALGB 9732: Final report of a randomized phase III intergroup trial of etoposide(VP-16) and cisplatin (DDP) with or without paclitaxel(TAX) and G-CSF in patients with extensive stage small cell lung cancer(ED-SCLC)

Michael R. Green, R. Marks, K. Kelly, 2003 .

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901

M. Socinski, J. Herndon, E. Vokes, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

A. Friedman, D. Bigner, J. Herndon, 2008, Clinical Cancer Research.

Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B.

J. Herndon, M. Green, G. Clamon, 1993, Journal of the National Cancer Institute.

Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study

J. Herndon, M. Green, S. Graziano, 2004, Cancer Chemotherapy and Pharmacology.

Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.

J. Holland, J. Herndon, Mark R. Green, 2002, Journal of the National Cancer Institute.

Resection of vestibular schwannomas.

J. Herndon, J. Sampson, 2011, Journal of neurosurgery.

Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.

H. Choy, J. Herndon, E. Vokes, 2005, Clinical lung cancer.

M. Socinski, J. Herndon, E. Vokes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.

J. W. Box, J. Herndon, M. Green, 2001, Lung cancer.

Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?

J. Holland, J. Herndon, Mark R. Green, 1999, Cancer.

Basic Biostatistical Methods in Oncology: Principles of Clinical Research Methods

J. Herndon, 1999 .

Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.

D. Sugarbaker, J. Herndon, Mark R. Green, 1998, Lung cancer.

Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer.

W. Richards, D. Sugarbaker, D. Harpole, 1996, The Annals of thoracic surgery.

Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence

D. Harpole, J. Herndon, D. Sabiston, 1995, Cancer.

Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.

M. Joshi, D. Harpole, J. Herndon, 2006, The Annals of thoracic surgery.

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

J. Holland, C. Desch, J. Herndon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity.

M. Socinski, J. Herndon, E. Vokes, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Pulmonary vein diameter, cross-sectional area, and shape: CT analysis.

H Page McAdams, Edith M Marom, J. Herndon, 2005, Radiology.

Clinical and dosimetric predictors of radiation-induced esophageal toxicity.

P. Maguire, S. Zhou, M. Anscher, 1999, International journal of radiation oncology, biology, physics.

Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium

M. Socinski, R. Clough, M. Anscher, 2004 .

Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807).

J. Herndon, Mark R. Green, G. Otterson, 2001, Lung cancer.

A Phase III Trial Evaluating the Combination of Cisplatin, Etoposide, and Radiation Therapy With or Without Tamoxifen in Patients With Limited-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study (9235)

J. Herndon, Mark R. Green, J. Bogart, 2005, American journal of clinical oncology.

Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.

K. Courneya, J. Mackey, P. Douglas, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic Therapy Type and Timing Effects on Radiation Necrosis Risk in HER2+ Breast Cancer Brain Metastases Patients Treated With Stereotactic Radiosurgery

J. Herndon, C. Anders, W. Giles, 2022, Frontiers in Oncology.

Measuring Disease-Free Survival and Cancer Relapse Using Medicare Claims From CALGB Breast Cancer Trial Participants (Companion to 9344)

Nicholas A. Christakis, N. Christakis, E. Lamont, 2006, Journal of the National Cancer Institute.

Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma

J. Herndon, Mark R. Green, N. Vogelzang, 1999, Cancer.

Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.

J. Herndon, N. Vogelzang, M. Green, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.

J. Herndon, J. Corson, Yasunosuke Suzuki, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).

N. Kemeny, J. Herndon, H. Lenz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas

A. Friedman, J. Cairncross, P. Burger, 1991, Neurology.

Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer

Susan Bauer-Wu, J. Holland, E. Small, 2006, Cancer.

A Phase II Trial of Carboplatin/Vinorelbine with Pegfilgrastim Support for the Treatment of Patients with Advanced Non-small Cell Lung Cancer

J. Herndon, J. Crawford, R. Riedel, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633.

D. Sugarbaker, J. Herndon, E. Vokes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.

J. Herndon, J. Rosenman, M. Green, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain

Allan H. Friedman, Gunilla C. Bentel, J. Gregory Cairncross, 1996 .

Dihydro‐5‐azacytidine and cisplatin in the treatment of malignant mesothelioma

J. Herndon, Mark R. Green, N. Vogelzang, 1998, Cancer.

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

R. Marks, K. Kelly, J. Herndon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sentinel Node Skills Verification and Surgeon Performance: Data From a Multicenter Clinical Trial for Early-Stage Breast Cancer

A. Giuliano, N. Hansen, K. Hunt, 2005, Annals of surgery.

Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.

R. Coleman, J. Herndon, E. Patz, 1997, AJR. American journal of roentgenology.

The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.

D. Harpole, J. Herndon, C. Allegra, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Reply to M.S. Lesniak

R. McLendon, D. Bigner, J. Herndon, 2011 .

A PHASE III RANDOMIZED PROSPECTIVE TRIAL OF EXTERNAL BEAM RADKlTHERAPY, MITOMYCIN C, CARMUSTINE, AND 6-~RCA~~NE FOR THE TREATMENT OF ADULTS WITH ANAPLAS'IK GLIOMA OF THE BRAIN

A. Friedman, J. Cairncross, S. Rosenfeld, 1995 .

Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.

E C Halperin, D. Bigner, J. Cairncross, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.

M. Dewhirst, R. Clough, M. Anscher, 2006, International journal of radiation oncology, biology, physics.

Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer.

J. Herndon, M. Green, G. Clamon, 2001, Clinical lung cancer.

A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.

J. Herndon, J. Crawford, S. Mehdi, 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Peak oxygen consumption and long‐term all‐cause mortality in nonsmall cell lung cancer

J. Herndon, D. Watson, G. Loewen, 2010, Cancer.

Long‐term adjustment of survivors of early‐stage breast carcinoma, 20 years after adjuvant chemotherapy

Larry Norton, J. Holland, L. Norton, 2003, Cancer.

Social support as a buffer to the psychological impact of stressful life events in women with breast cancer

J. Holland, C. Viscoli, L. Norton, 2001, Cancer.

Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial

P. Douglas, J. Herndon, L. Jones, 2021, Journal of cachexia, sarcopenia and muscle.

Quality of life outcomes are equivalent after lobectomy in the elderly.

D. Harpole, J. Herndon, T. D’amico, 2008, The Journal of thoracic and cardiovascular surgery.

Rethinking Autoantibody Signature Panels for Cancer Diagnosis

E. Gottlin, M. Campa, J. Herndon, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Sequestration of T-cells in bone marrow in the setting of glioblastoma and other intracranial tumors

B. Nahed, W. Curry, R. Martuza, 2018, Nature Medicine.

Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761.

G. Patterson, J. Herndon, R. Kratzke, 2002, The Journal of thoracic and cardiovascular surgery.

Clinical Stage I Non-small Cell Lung Cancer Including FDG-PET Imaging: Sites and Time to Recurrence

R. Coleman, J. Herndon, E. Patz, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience.

J. Herndon, R. Dillman, M. Green, 1994, Seminars in oncology.

Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index.

M A Hlatky, R. Califf, D. Pryor, 1991, The American journal of cardiology.

The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

R. Coleman, J. Herndon, E. Patz, 1998, Cancer.

The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.

J. Herndon, C. Kesserwan, C. Counter, 2007, Cancer research.

Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.

John E. Connolly, J. Herndon, E. Patz, 2000, AJR. American journal of roentgenology.

Economic outcomes of breast cancer survivorship: CALGB study 79804

E. Winer, J. Herndon, J. Weeks, 2005, Breast Cancer Research and Treatment.

A Phase I Study of Dose-Dense Topotecan Given Upfront to Standard Therapy in Patients with Small Cell Lung Cancer

J. Herndon, J. Crawford, J. Garst, 2006, Clinical drug investigation.

Therapy choices among older patients with lung carcinoma

J. Herndon, Mark R. Green, G. Clamon, 2002, Cancer.

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer

J. Herndon, E. Vokes, M. Kelley, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B.

J. Herndon, E. Vokes, M. Green, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular biologic substaging of stage I lung cancer according to gender and histology.

D. Harpole, J. Herndon, T. D’amico, 2000, The Annals of thoracic surgery.

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.

Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival

J. Herndon, E. Patz, J. Hoang, 2009, Cancer.

Long-term complication risk after very high dose thoracic radiotherapy

R. Clough, M. Anscher, J. Herndon, 2002 .

Chemoradiotherapy (CRT) and gefitinib (G) in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial.

M. Edelman, P. Janne, J. Herndon, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.

J. Herndon, E. Patz, H. McAdams, 2000, Radiology.

Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer.

P C Goodman, D. Harpole, J. Herndon, 2000, Chest.

Spinal cord dose in limited stage small cell lung cancer: a preliminary quality assurance review committee (QARC) report on CALGB 39808, using target thoracic radiotherapy (TRT) doses of 60 – 70 Gy

J. Herndon, A. Turrisi, Mark R. Green, 2001 .

Outcomes in Patients With 4 to 10 Brain Metastases Treated With Dose-Adapted Single-Isocenter Multitarget Stereotactic Radiosurgery: A Prospective Study

F. Yin, J. Herndon, C. Anders, 2021, Advances in radiation oncology.

High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

J. Herndon, G. Strauss, N. Vogelzang, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer.

D. Sugarbaker, J. Herndon, Mark R. Green, 2002, Clinical lung cancer.

Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants

N. Christakis, E. Lamont, R. Schilsky, 2008, Medical care.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

M. Socinski, R. Clough, M. Anscher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer.

J. Herndon, J. Crawford, M. Kelley, 2006, Lung cancer.

A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.

E C Halperin, G C Bentel, L Gaspar, 1996, International journal of radiation oncology, biology, physics.

Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study.

J. Herndon, C. Cirrincione, M. Green, 1995, Lung cancer.

Neurofibromatosis 1, and Not TP53, Seems to Be the Main Target of Chromosome 17 Deletions in De Novo Acute Myeloid Leukemia

J. Herndon, R. Petersen, D. Tyler, 2006 .

Cancer surveillance behaviors and psychosocial factors among long‐term survivors of breast cancer

J. Herndon, M. Katz, E. Paskett, 2009, Cancer.

Biomarkers to help guide management of patients with pulmonary nodules.

E. Gottlin, M. Campa, J. Herndon, 2013, American journal of respiratory and critical care medicine.

CALGB Study 9431: A randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III non-small cell lung cancer (NSCLC)

Michael R. Green, J. Herndon, E. Vokes, 2000 .

Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer.

D. Harpole, J. Herndon, E. Patz, 2001, Lung cancer.

Safety of nivolumab in combination with dendritic cell vaccines in recurrent high-grade glioma.

J. Herndon, E. Lipp, H. Friedman, 2019, Journal of Clinical Oncology.

Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761.

J. Herndon, R. Kratzke, Mark R. Green, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Stage I nonsmall cell lung cancer : a multivariate analysis of treatment methods and patterns of recurrence

J. Herndon, D. Sabiston, D. Harpole, 1995 .

Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non‐small cell lung cancer

J. Herndon, J. Crawford, K. Leopold, 1994, Cancer.

Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.

J. Herndon, E. Vokes, Mark R. Green, 2000, Lung cancer.

Reply to M.C. Chamberlain

D. Bigner, J. Herndon, A. Heimberger, 2011 .

Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer.

J. Herndon, E. Vokes, M. Green, 1997, Seminars in oncology.

Initial cohort toxicity evaluation for chemoradiotherapy (CRT) and ZD1839 in stage III non-small cell lung cancer (NSCLC): A CALGB stratified phase II trial.

J. Herndon, E. Vokes, T. Dipetrillo, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

121 Comparison of pre-operative thoracic radiation therapy (TRT) to pre-operative chemotherapy (CT) in surgically staged IIIA(N2) non-small cell lung cancer (NSCLC): Initial results of cancer and leukemia group B (CALGB) phase III protocol 9134

D. Sugarbaker, J. Herndon, Mark R. Green, 1997 .

Relation between p53 overexpression and established prognostic factors in breast cancer.

J. Herndon, A. Davidoff, J. Iglehart, 1991, Surgery.

Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning.

J. Holland, D. Cella, J. Herndon, 2001, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481)

N. Kemeny, J. Herndon, D. Schrag, 2005 .